Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774928 | 0.87 | MAPT (0.53) | HSP90AA1CYP11B2KDM4E | |
| SCHEMBL5774933 | 0.77 | HSP90AA1 (0.36) | HSP90AA1KDM4EPOLBL3MBTL1HRH3 | |
| SCHEMBL30188618 | 0.77 | HSP90AA1 (0.50) | HSP90AA1KDM4EPOLBHRH3 | |
| SCHEMBL5777572 | 0.75 | HSP90AA1 (0.41) | HSP90AA1 | |
| SCHEMBL6282952 | 0.74 | HSP90AA1 (0.40) | HSP90AA1 | |
| SCHEMBL30405316 | 0.74 | HSP90AA1 (0.42) | HSP90AA1 | |
| SCHEMBL28907586 | 0.74 | HSP90AA1 (0.42) | HSP90AA1 | |
| SCHEMBL5776735 | 0.73 | HSP90AA1 (0.43) | HSP90AA1 | |
| SCHEMBL5774769 | 0.72 | HSP90AA1 (0.43) | HSP90AA1 | |
| SCHEMBL5777878 | 0.71 | MAPT (0.58) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | HSP90AA1 1452/4885CYP11B2 26/4885KDM4E 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.